simcyp® v21 (Simcyp)
90
Structured Review
Simcyp
simcyp® v21
Simcyp® V21, supplied by Simcyp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/simcyp+v21/simcyp+v19/pm39934586-93-16-16
Average 90 stars, based on 1 article reviews
Simcyp® V21, supplied by Simcyp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/simcyp+v21/simcyp+v19/pm39934586-93-16-16
Average 90 stars, based on 1 article reviews
simcyp® v21 - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
other:Article Title: 2023 Annual Meeting American College of Clinical Pharmacology®. Article Snippet: Article Title: Physiologically based pharmacokinetic modeling for development and applications of a virtual celiac disease population using felodipine as a model drug. Article Snippet: The range utilized to evaluate parameter sensitivity was based on the physiologically relevant minimum and maximum values in Article Title: Static Versus Dynamic Model Predictions of Competitive Inhibitory Metabolic Drug-Drug Interactions via Cytochromes P450: One Step Forward and Two Steps Backwards. Article Snippet: Predicted area under the plasma concentration–time profile ratios for substrates (AUCr = AUC (presence of precipitant)/ Article Title: Lamivudine and Emtricitabine Dosing Proposal for Children with HIV and Chronic Kidney Disease, Supported by Physiologically Based Pharmacokinetic Modelling Article Snippet: Since population models reflecting children with CKD are not available in Article Title: Physiologically-based pharmacokinetic model to investigate the effect of pregnancy on risperidone and paliperidone pharmacokinetics: Application to a pregnant woman and her neonate. Article Snippet: According to the Australian categorization system for prescribing medicines in pregnancy,38 RIS is a C category drug, implying that it may cause or is suspected of causing harm to the human fetus or neonate with no malformations.38 RIS is an intermediate Article Title: Physiologically based pharmacokinetic modeling for development and applications of a virtual celiac disease population using felodipine as a model drug. Article Snippet: See the T erm s and C onditions (https://onlinelibrary.w iley.com /term s-and-conditions) on W iley O nline L ibrary for rules of use; O A articles are governed by the applicable C reative C om m ons L icense 812 | SALEM et al. T A B L E 1 Input parameters for development of felodipine PBPK model. Parameter Value References Physchem parameter MW 384.20 14 Log Po:w 4.18 14,15 Compound type Neutral 16 B/P 0.7 16,17 Follow- up 0.0048 16 Main plasma binding protein HSA Assumed Absorption ADAM Consider extended- release formulation option Fugut 0.12 Fitted to capture FG of around 0.4d Log (Km:w) 4.805 Fitted in SIVA to solubility data (see Appendix S1) MechPeff model Total concentration (Bound + Unbound)e Ptrans,0 (10 −6 cm/s) 93,522 LogP Method 2 Regional Permeability, Peff (10 −4 cm/s) (no micelles) Duodenum = 12.0 Jejunum I = 19.0 Jejunum II = 13.1 Ileum I = 2.7 Ileum II = 2.7 Ileum III = 2.7 Ileum IV = 2.6 Colon = 0.83 Predicted with the MechPeff Model Absorption rate scalars, Globala 5.68 Based on lactulose: mannitol clinical studies Formulation Monolith controlled/modified release (CR/MR) Dissolution data Dissolution profile Estimatedb Transit time Segregated transit timesc Values related to CeD population is in Table S2 Distribution Full PBPK Vss (L/kg) (Landahl1988) 2.41 Predicted Kp method Predicted with method 2 Kp scalar estimated to fit i.v. infusion data 0.6685 Optimized for best fit with i.v. data Elimination CLiv (L/h) 49.4 18 CLpo (L/h) 619 19 CLint CYP3A4 (μL/min/pmol of CYP3A4) 83.1485 Predicted from CLiv fm CYP3A4 (%) 100 20 Renal clearance (L/h) 49.4 18 Abbreviations: ADAM, advanced dissolution, absorption, and metabolism; CeD, celiac disease; CL, clearance; IVIVC, in vitro- in vivo correlation; MW, molecular weight; PBPK, physiologically- based pharmacokinetic. aApplied only in severe CeD to account for leakiness of small intestine in moderate and severe villous atrophy.21 bPredicted through Concentration Assay:Article Title: Use of Developmental Midazolam and 1-Hydroxymidazolam Data with Pediatric Physiologically Based Modeling to Assess Cytochrome P450 3A4 and Uridine Diphosphate Glucuronosyl Transferase 2B4 Ontogeny In Vivo. Article Snippet: .. Predicted and observed concentration time profiles for 1-OHMDZ in van Groen et al (2019), Reed et al (2002) and Neupane et al 2022 comparing the default UGT2B4 ontogeny profile in |
